- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
2D Images and Tomosynthesis Matches Standard of FFDM and Tomosynthesis
Reconstructed 2D images, with no radiation exposure, and tomosynthesis are comparable to full field digital mammography plus DBT in screening mammograms.
Combining reconstructed 2D images and digital breast tomosynthesis (DBT) provides adequate imaging comparable to full-field digital mammography (FFDM) plus DBT, according to a study published in the journal Radiology.
Researchers from Norway undertook a clinical trial to compare imaging accuracy of reconstructed 2D images and DBT with the FFDM plus DBT. A total of 24,901 screening examinations were performed on women who were between the ages of 50 and 69 (mean age, 59.2). Craniocaudal and mediolateral oblique views of each breast were acquired by mammography, and FFDM and DBT views of each breast were acquired during a single breast compression per view.
The screening took place over two periods: Period 1 took place from November 22, 2010 to December 21, 2011 (12,631 women), and period 2 from January 20, 2012 to December 19, 2012 (12,270 women). The images were compared in terms of cancer detection and false-positive rates.
The following cancer detection rates and false positives were found:
The authors concluded that the tomosynthesis combination “performed comparably to FFDM plus DBT and is adequate for routine clinical use when interpreting screening mammograms.”
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
